Danaher Corporation (DHR) earnings on July 21, 2026
More Danaher Corporation earnings
Prior outlook: No statistical edge
Danaher shares plunged after earnings, closing down 12.4% as investors reacted strongly to the report.
DHR price around the earnings
179.01
Change: -11.3%
2026-07-21, 20:00 UTC
Start of the measured window
End of the measured window
166.67
178.94
191.21
203.48
201.83
July 21, 2026
- Price: green if it ends above the starting price; red if it ends below
- Start of the measured window
- End of the measured window
- Market open
- Starting price
Prior thesis
Prior outlook: No statistical edge
- Thesis published
- Results released
Context analyzed before publication
Analysts
Evidence
- Analyst consensus
- Strong buy
- Consensus average (1-5)
- 1.5
- Analysts covering the stock
- 23
- Average price target
- 242.52
- Lowest price target
- 200
- Highest price target
- 310
- Upside to price target
- 20.6%
- Quarterly earnings growth
- 7.9%
- Revenue growth
- 3.7%
- Forward EPS
- 9.27
- Trailing EPS
- 5.09
- Analyst moves in the last 60 days
- 4
- July 6, 2026 · Evercore ISI Group: Maintains rating (Outperform → Outperform)
- June 11, 2026 · Piper Sandler: Initiates coverage (Neutral → Neutral)
- June 3, 2026 · HSBC: Maintains rating (Buy → Buy)
- May 27, 2026 · Citigroup: Downgrades rating (Buy → Neutral)
News and sentiment
Evidence
Sentiment
- Sentiment
- Constructive
- Mention volume
- Low
- Normalized volume
- 33%
News
Sources (2)
- Linden Capital Partners And Audax Private Equity To Sell StatLab Medical Products To Leica Biosystems, An Operating Company Of Danaher; Financial Terms Not Disclosed (opens in a new tab) — Benzinga
- Evercore ISI Group Maintains Outperform on Danaher, Lowers Price Target to $230 (opens in a new tab) — Benzinga
Technicals
Evidence
- Average true range (ATR)
- 2.1%
- Distance to 52-week high
- -16.6%
- 14-day change (14d)
- +4.5%
- 30-day change (30d)
- +8.0%
- 30-day relative strength
- +8.0%
- Benchmark change (0d)
- +0.0%
- Nearest support
- 200.5
- Nearest resistance
- 203.08
- Volume accumulation ratio (14d / 46d)
- 0.8
Trends
Evidence
- Average earnings surprise
- +6.9%
- April 21, 2026: actual EPS 2.06 vs estimate 1.94 (surprise +6.5%)
- January 28, 2026: actual EPS 2.23 vs estimate 2.19 (surprise +2.0%)
- October 21, 2025: actual EPS 1.89 vs estimate 1.72 (surprise +9.8%)
- July 22, 2025: actual EPS 1.8 vs estimate 1.64 (surprise +9.5%)
Expected move
There is no implied-move data available for this event.
Reactions over its last 20 earnings
- Median move
- 3.9%
- 75th percentile move
- 6%
- 90th percentile move
- 8.8%
- Up / down moves
- 9 / 11
- Average up move
- +4.7%
- Average down move
- -3.8%
Monitoring and close
What Danaher Corporation reported
- Status
- Finished
| Actual EPS | 1.94 |
|---|---|
| EPS estimate | 1.83 |
| EPS surprise | +6.0% |
| Revenue | $6,265 million |
| Revenue estimate | $6,102 million |
| Revenue surprise | +2.7% |
Danaher beats Q2 2026 estimates with $6.3B revenue, but margin contraction and weak core revenue forecast spark pessimism, sending shares tumbling.
Sources (29)
- Why Danaher (DHR) Shares Are Falling Today (opens in a new tab) — StockStory
- Why Repligen (RGEN) Stock Is Trading Lower Today (opens in a new tab) — StockStory
- Danaher Corp (DHR) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and Raised EPS Guidance (opens in a new tab) — GuruFocus.com
- SpaceX, Micron, Western Digital, Coinbase, Danaher, and More Stocks That Explain Today’s Market (opens in a new tab) — Yahoo
- SpaceX, Micron, Western Digital, Sandisk, Danaher, and More Stocks That Explain Today’s Market (opens in a new tab) — Barrons.com
- Behind Danaher’s Worst Stock Selloff in Over 20 Years (opens in a new tab) — Barrons.com
- Health Care Roundup: Market Talk (opens in a new tab) — The Wall Street Journal
- Danaher Q2 Earnings Beat Estimates, Life Sciences Sales Up Y/Y (opens in a new tab) — Zacks
- Danaher Lifts Full-Year Profit Outlook Following Second-Quarter Beat, Tempers Sales Guidance (opens in a new tab) — MT Newswires
- Behind Danaher’s Worst Stock Selloff in Over 30 Years (opens in a new tab) — Barrons.com
- Why Danaher Stock Just Tanked 14% (opens in a new tab) — Benzinga
- Danaher Q2 Earnings Call Highlights (opens in a new tab) — MarketBeat
- Transcript: Danaher Q2 2026 Earnings Conference Call (opens in a new tab) — Benzinga
- Compared to Estimates, Danaher (DHR) Q2 Earnings: A Look at Key Metrics (opens in a new tab) — Zacks
- Danaher Plummets After One Segment Comes In 'Surprisingly Soft' (opens in a new tab) — Investor's Business Daily
- Danaher Q2 Earnings Review: Nothing Exciting For Me To Buy This Dip (opens in a new tab) — SeekingAlpha
- Danaher Corporation (DHR) Q2 2026 Earnings Call Transcript (opens in a new tab) — SeekingAlpha
- Danaher Posts Q2 Results, Joins Calix, Equifax And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session (opens in a new tab) — Benzinga
- Danaher shares slide despite second-quarter earnings and revenue beat (DHR) (opens in a new tab) — InvestorsHub
- Danaher (DHR) Q2 Earnings and Revenues Top Estimates (opens in a new tab) — Zacks
- Danaher shares tumble despite earnings beat (opens in a new tab) — Investing.com
- Danaher (NYSE:DHR) Posts Better-Than-Expected Sales In Q2 CY2026 But Stock Drops (opens in a new tab) — StockStory
- Danaher Sees Q3 Non-GAAP Core Revenue To Increase In 2.0% To 3.0% Range YoY, And FY26 Non-GAAP Core Revenue To Increase In 3.0% To 4.0% Range YoY (opens in a new tab) — Benzinga
- Danaher Sees Q3 Expects Non-GAAP Core Revenue To Increase In 2.0% To 3.0% Range YoY, And FY26 Non-GAAP Core Revenue Growth 3.0% To 4.0% Range YoY (opens in a new tab) — Benzinga
- Danaher Raises FY2026 Adj EPS Guidance from $8.35-$8.55 to $8.45-$8.60 vs $8.45 Est (opens in a new tab) — Benzinga
- Danaher Q2 Adj. EPS $1.94 Beats $1.83 Estimate, Sales $6.265B Beat $6.102B Estimate (opens in a new tab) — Benzinga
- Danaher Reports Second Quarter 2026 Results (opens in a new tab) — Yahoo
- Danaher Corporation 2026 Q2 - Results - Earnings Call Presentation (opens in a new tab) — SeekingAlpha
- Earnings per share: $1.94 vs $1.85 expected — above expectations. Revenue: $6.26B vs $6.16B expected. — Finnhub
Pre-market second reading after the results
Heading into the open, the figures don't clearly confirm the prior scenario. In past cases, 418 out of 418 similar scenarios (94%) were pessimistic.
How the stock reacted
- Consolidated
- -12.4%
- Max move
- -17.8%
No verdict: the outlook took no direction, so there is nothing to score as a hit or a miss.